{ "data": [ { "id": "stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "url": "https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "indicator": { "slug": "alzheimer-s-disease-innovative-drug-clinical-trial-approvals-multi-year-total", "name": "Alzheimer's disease innovative drug clinical trial approvals (multi-year total)", "definition": "Number of innovative drugs approved to initiate clinical trials for the treatment of Alzheimer's disease during the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2024-12-31", "type": "year" }, "value": 8, "value_text": "eight", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "In the past two years, it has approved clinical trials for eight innovative drugs that could potentially treat the disease.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "bibtex": "@misc{nmpa2024alzheimera9av3h,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_9SEHGAYSGEVZP40MYK9NVXJ81A", "url": "https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A", "indicator": { "slug": "antibody-drug-conjugate-approvals", "name": "Antibody-drug conjugate approvals", "definition": "Total number of antibody-drug conjugates granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 3, "value_text": "three", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Established Modalities Maintain a Larger Presence", "quote": "BsAbs and peptide therapies saw four new entrants each, while ADCs, cell therapies, and fusion proteins received three approvals each.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A", "bibtex": "@misc{dia2025antibodyvxj81a,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_9SEHGAYSGEVZP40MYK9NVXJ81A},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "url": "https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "indicator": { "slug": "approved-class-1-innovative-drugs", "name": "Approved Class 1 innovative drugs", "definition": "Total number of Class 1 innovative drugs approved for marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 76, "value_text": "76个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况", "document_url": "http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html", "document_type": "press_release", "locator": "大众新闻大众日报记者提问", "quote": "2025年批准上市的76个1类创新药中，既有我国本土企业原创的“全球新”，也有部分跨国企业在我国实现的“全球首发”。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/4/15/art_14_20221.html. Via StatOrigin, https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX", "bibtex": "@misc{nhsa2025approvedckwyjx,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_5XWSVWS6KHPM8RN9H08ECKWYJX},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/4/15/art\\_14\\_20221.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "url": "https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "indicator": { "slug": "approved-class-1-innovative-drugs-half-year", "name": "Approved Class 1 innovative drugs (half year)", "definition": "Total number of Class 1 innovative drugs approved for marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 38, "value_text": "38个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "记者今天从国家药监局获悉，最新统计显示，今年上半年我国批准38个1类创新药上市。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9", "bibtex": "@misc{nhsa2026approved10svf9,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KCA1ABEFQSZFJWEMVZ7Y10SVF9},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1WGYBP9BMEKJBY30RP8KX65K3G", "url": "https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G", "indicator": { "slug": "approved-drug-marketing-registration-applications-half-year", "name": "Approved drug marketing registration applications (half year)", "definition": "Total number of drug marketing registration applications approved by the regulatory authority." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 2318, "value_text": "2318件", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "国家药监局药品注册管理司副司长蓝恭涛表示，截至6月底，国家药监局今年共批准药品上市注册申请2318件，其中“全球新”创新药38个，包括20个化学药品，17个生物制品和1个中药。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G", "bibtex": "@misc{nhsa2026approvedx65k3g,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1WGYBP9BMEKJBY30RP8KX65K3G},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "url": "https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "indicator": { "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies", "name": "Approved innovative drugs designated as breakthrough therapies", "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4", "bibtex": "@misc{statecouncil2024approvedqdwka4,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_0SEXJ7ZASPFSZTGZC1KYQDWKA4},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "url": "https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "indicator": { "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies", "name": "Approved innovative drugs designated as breakthrough therapies", "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "bibtex": "@misc{nmpa2024approvedq9g5c2,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_H8FD1RAF0HRJDA674FRB5MNFWX", "url": "https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX", "indicator": { "slug": "approved-innovative-drugs-growth-rate", "name": "Approved innovative drugs growth rate", "definition": "Year-on-year percentage growth rate of innovative drugs approved for marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 58.3, "value_text": "58.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Ministry of Commerce of China", "org_short_name": "MOFCOM", "org_url": "https://www.mofcom.gov.cn", "org_tier": 1, "document_title": "2025年我国批准创新药76个 对外授权超千亿美元", "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html", "document_type": "press_release", "locator": "2025年我国批准创新药76个 对外授权超千亿美元", "quote": "从国家药品监督管理局获悉，2025年我国创新药审评审批取得历史性突破，全年共批准上市创新药76个，较2024年的48个大幅增长58.3%，创历史新高；同时，数据显示，中国创新药对外授权（BD）交易总金额达1356.55亿美元，交易数量达157笔，双双刷新纪录。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Ministry of Commerce of China. (2025). 2025年我国批准创新药76个 对外授权超千亿美元. Retrieved September 17, 2026, from https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Via StatOrigin, https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX", "bibtex": "@misc{mofcom2025approved5mnfwx,\n author = {{Ministry of Commerce of China}},\n title = {2025年我国批准创新药76个 对外授权超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H8FD1RAF0HRJDA674FRB5MNFWX},\n note = {Original source: https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "url": "https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "indicator": { "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms", "name": "Approved innovative drugs with new targets or mechanisms", "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 11, "value_text": "11个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3", "bibtex": "@misc{nhsa2025approvedqnryd3,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VXVARPPSBWC8A6ZCKDBPQNRYD3},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "url": "https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "indicator": { "slug": "approved-innovative-drugs-with-new-targets-or-mechanisms-half-year", "name": "Approved innovative drugs with new targets or mechanisms (half year)", "definition": "Total number of innovative drugs with novel biological targets or mechanisms of action approved for marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2026-01-01", "end": "2026-06-30", "type": "point" }, "value": 11, "value_text": "11个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元", "document_url": "http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html", "document_type": "press_release", "locator": "今年38个1类创新药已获批上市 11款新靶点、新机制药均为国产", "quote": "据介绍，今年上半年批准上市的38个创新药中，有11个是新靶点、新机制的药品，并且均为自主研发的国产创新药；而2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2026). 国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/7/14/art_14_21423.html. Via StatOrigin, https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA", "bibtex": "@misc{nhsa2026approved3gv1va,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 我国上半年创新药对外授权交易额超千亿美元},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_RYGSZH3DKE8N9CQ1G9B03GV1VA},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/7/14/art\\_14\\_21423.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "url": "https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "indicator": { "slug": "approved-novel-drugs-in-breakthrough-therapy-programs", "name": "Approved novel drugs in breakthrough therapy programs", "definition": "Number of approved novel drugs that participated in breakthrough therapy programs during clinical development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "bibtex": "@misc{nmpa2024approvedvn2y2d,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "url": "https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "indicator": { "slug": "beneficiaries-of-negotiated-reimbursement-drugs", "name": "Beneficiaries of negotiated reimbursement drugs", "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 830, "value_text": "8.3亿人次", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "截至2024年10月底，协议期内谈判药品累计受益8.3亿人次，累计为患者减负超8800亿元，充分彰显党和政府对人民健康福祉的高度关切。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4", "bibtex": "@misc{nhsa2024beneficiaries9mksd4,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YBYHGK0ZP18XJ17TE3M39MKSD4},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R7VPZ3Y198V455WDHSD3E3W11N", "url": "https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N", "indicator": { "slug": "beneficiaries-of-negotiated-reimbursement-drugs", "name": "Beneficiaries of negotiated reimbursement drugs", "definition": "Cumulative count of patient visits or individuals benefiting from price-negotiated reimbursement medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 830, "value_text": "8.3亿人次", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保基金为协议期内谈判药品支付累计超过3500亿元，惠及患者8.3亿人次。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N", "bibtex": "@misc{statecouncil2024beneficiariese3w11n,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R7VPZ3Y198V455WDHSD3E3W11N},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FXX75R17XTD8EC3NEN7WD7C6RW", "url": "https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW", "indicator": { "slug": "bioequivalence-trials", "name": "Bioequivalence trials", "definition": "Total number of registered bioequivalence trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2218, "value_text": "2218项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW", "bibtex": "@misc{nhsa2025bioequivalenced7c6rw,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FXX75R17XTD8EC3NEN7WD7C6RW},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "url": "https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "indicator": { "slug": "bioequivalence-trials-share", "name": "Bioequivalence trials share", "definition": "Share of bioequivalence trials in total registered clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 42.5, "value_text": "42.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "试验包括新药临床试验和生物等效性试验", "quote": "其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ", "bibtex": "@misc{nhsa2025bioequivalencepfnkzq,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JM8R59GFDJR6JR50N6ESCFDKCW", "url": "https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW", "indicator": { "slug": "biologic-therapy-approvals", "name": "Biologic therapy approvals", "definition": "Total number of biological therapeutics granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 40, "value_text": "40", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "quote": "These include 80 conventional medicines such as small molecules, peptides, and nucleic acids, as well as 40 biologic therapies such as monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW", "bibtex": "@misc{dia2025biologiccfdkcw,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JM8R59GFDJR6JR50N6ESCFDKCW},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VTRXBDTB1NEFN7JEV4E02EV9S9", "url": "https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9", "indicator": { "slug": "bispecific-antibody-approvals", "name": "Bispecific antibody approvals", "definition": "Total number of bispecific antibody therapies authorized for commercial marketing." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "four", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Established Modalities Maintain a Larger Presence", "quote": "BsAbs and peptide therapies saw four new entrants each, while ADCs, cell therapies, and fusion proteins received three approvals each.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9", "bibtex": "@misc{dia2025bispecific2ev9s9,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VTRXBDTB1NEFN7JEV4E02EV9S9},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EVH61V5CNVGR3ADB2EDGQSS2AM", "url": "https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM", "indicator": { "slug": "breast-cancer-drug-approvals", "name": "Breast cancer drug approvals", "definition": "Number of new pharmaceutical therapies approved for breast cancer indications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 9, "value_text": "nine", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "The Cancer Sector Continues to Attract the Most Players", "quote": "Breast cancer was the most active area with a total of nine new entrants, including the PI3Kα inhibitor inavolisib, the AKT inhibitor capivasertib, the TROP2- and HER2-targeted ADCs datopotamab deruxtecan and trastuzumab botidotin respectively, as well as multiple CDK inhibitors, namely bireociclib, lerociclib, tibremciclib, fovinaciclib, and culmerciclib.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM", "bibtex": "@misc{dia2025breastqss2am,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EVH61V5CNVGR3ADB2EDGQSS2AM},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "url": "https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "indicator": { "slug": "category-1-innovative-drugs-added-to-national-health-insurance-catalog", "name": "Category 1 innovative drugs added to national health insurance catalog", "definition": "Number of category 1 innovative drugs newly added to the national health insurance drug catalog." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "document_url": "https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录", "quote": "经相应程序，本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临床没有供应或可被其他药物更好替代的药品（其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号）。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2025/12/7/art_14_18972.html. Via StatOrigin, https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9", "bibtex": "@misc{nhsa2025categorywkgds9,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QQG2RVEKCGHD2E7P4ZJTWKGDS9},\n note = {Original source: https://www.nhsa.gov.cn/art/2025/12/7/art\\_14\\_18972.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T1MJW4WJHJWYPQ2W486WCAHK5H", "url": "https://statorigin.org/stat/stat_T1MJW4WJHJWYPQ2W486WCAHK5H", "indicator": { "slug": "cell-therapy-approvals", "name": "Cell therapy approvals", "definition": "Total number of cell therapies granted regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 3, "value_text": "three", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Established Modalities Maintain a Larger Presence", "quote": "BsAbs and peptide therapies saw four new entrants each, while ADCs, cell therapies, and fusion proteins received three approvals each.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_T1MJW4WJHJWYPQ2W486WCAHK5H", "bibtex": "@misc{dia2025cellcahk5h,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T1MJW4WJHJWYPQ2W486WCAHK5H},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1D7K70JPV4F1B4X53S0XCSEM96", "url": "https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96", "indicator": { "slug": "centralized-procurement-drugs-added-to-national-reimbursement-drug-list", "name": "Centralized procurement drugs added to national reimbursement drug list", "definition": "Number of drugs winning bids in volume-based procurement directly included into a national reimbursement drug list." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-11-28", "type": "point" }, "value": 2, "value_text": "2种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "在今年的调整中，有91种药品新增进入国家医保药品目录，其中89种以谈判/竞价方式纳入，另有2种国家集采中选药品直接纳入，同时43种临床已被替代或长期未生产供应的药品被调出。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96", "bibtex": "@misc{nhsa2024centralizedcsem96,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1D7K70JPV4F1B4X53S0XCSEM96},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "url": "https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "indicator": { "slug": "class-1-innovative-drug-clinical-trials", "name": "Class 1 innovative drug clinical trials", "definition": "Number of clinical trials registered for Class 1 innovative drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2171, "value_text": "2171项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5", "bibtex": "@misc{nhsa2025classkpdrg5,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_EHZYM6Q4T84P4ZPNXP7TKPDRG5},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_XBDEETFHREBH7K3QRCNXDVAHPE", "url": "https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE", "indicator": { "slug": "class-1-innovative-drug-clinical-trials-growth-rate", "name": "Class 1 innovative drug clinical trials growth rate", "definition": "Year-over-year percentage growth in Class 1 innovative drug clinical trial registrations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4.1, "value_text": "4.1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE", "bibtex": "@misc{nhsa2025classdvahpe,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XBDEETFHREBH7K3QRCNXDVAHPE},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "url": "https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "indicator": { "slug": "class-1-innovative-drug-clinical-trials-share", "name": "Class 1 innovative drug clinical trials share", "definition": "Share of Class 1 innovative drug clinical trials among all new drug clinical trials." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 72.4, "value_text": "72.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "新药临床试验近六成 其中超七成是创新药", "quote": "报告显示，2025年我国登记的2997项新药临床试验中，1类创新药有2171项，占比72.4%，同比增长4.1%；1类创新药临床试验抗肿瘤药物占比较高，占总体的37.5%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP", "bibtex": "@misc{nhsa2025classvtw4mp,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8SY5MKW0ZBKK7QPKFSF9VTW4MP},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 15, "value_text": "15%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS", "bibtex": "@misc{iqvia2023clinicalbjmgcs,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCS},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 13, "value_text": "13%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV", "bibtex": "@misc{iqvia2023clinicalbjmgcv,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCV},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2019-01-01", "end": "2019-12-31", "type": "year" }, "value": 10, "value_text": "10%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Key findings:", "quote": "Country utilization by region has shifted significantly in the past five years with Western Europe share declining by 21% (from 32% to 25% of global total) and Eastern Europe share decreasing 33% (from 17% to 11%), as North America share increased 17% (from 19% to 23%) and China share increased 57% (from 10% to 15%).", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2019). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR", "bibtex": "@misc{iqvia2019clinicalbjmgcr,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2019},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCR},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "url": "https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5215, "value_text": "5215项", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "quote": "国家药监局药审中心副主任杨志敏介绍，2025年，国家药监局收到临床试验登记总量5215项，同比增长6.4%，创历史新高，较2020年翻一番。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC", "bibtex": "@misc{nhsa2025clinicalc7jspc,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KRH03AR8MZ5JYVWYGK6AC7JSPC},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "url": "https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 4300, "value_text": "4,300", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2023). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW", "bibtex": "@misc{statecouncil2023clinicalrp4bqw,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_BPHX2XQA3EV4G1QEV7GMRP4BQW},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3E4RA23KG2414RKK4KT0JHAKQ4", "url": "https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 3410, "value_text": "3,410", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2022). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4", "bibtex": "@misc{statecouncil2022clinicaljhakq4,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3E4RA23KG2414RKK4KT0JHAKQ4},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KJM61RPXMKJJR9W1K7556F9HW5", "url": "https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5", "indicator": { "slug": "clinical-trial-registrations", "name": "Clinical trial registrations", "definition": "Number of clinical trials registered on the International Clinical Trials Registry Platform." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2021-01-01", "end": "2021-12-31", "type": "year" }, "value": 3358, "value_text": "3,358", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "China scales up support for clinical trials, accelerating drug development", "document_url": "https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html", "document_type": "press_release", "locator": "China scales up support for clinical trials, accelerating drug development", "quote": "A total of 3,358 clinical trials of drugs were registered in China in 2021, 3,410 in 2022, and 4,300 in 2023, indicating continuous growth, according to an industry report.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2021). China scales up support for clinical trials, accelerating drug development. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202405/21/content_WS664be047c6d0868f4e8e74ae.html. Via StatOrigin, https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5", "bibtex": "@misc{statecouncil2021clinical6f9hw5,\n author = {{State Council of China}},\n title = {China scales up support for clinical trials, accelerating drug development},\n year = {2021},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KJM61RPXMKJJR9W1K7556F9HW5},\n note = {Original source: https://english.www.gov.cn/news/202405/21/content\\_WS664be047c6d0868f4e8e74ae.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "url": "https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "indicator": { "slug": "clinical-trial-registrations-growth-rate", "name": "Clinical trial registrations growth rate", "definition": "Year-over-year percentage growth in total drug clinical trial registrations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 6.4, "value_text": "6.4%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "document_url": "http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html", "document_type": "press_release", "locator": "从“0”到“1”创新能力增强 我国新药研发热度持续攀升", "quote": "国家药监局药审中心副主任杨志敏介绍，2025年，国家药监局收到临床试验登记总量5215项，同比增长6.4%，创历史新高，较2020年翻一番。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM", "bibtex": "@misc{nhsa2025clinicalvs1pym,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 从“0”到“1”创新能力增强 我国新药研发热度持续攀升},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Z4MDH9RBNDJCCCKW2KAGVS1PYM},\n note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\\_14\\_21076.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8V30JK5MA813ART823V6ZF2J7Y", "url": "https://statorigin.org/stat/stat_8V30JK5MA813ART823V6ZF2J7Y", "indicator": { "slug": "conventional-medicine-approvals", "name": "Conventional medicine approvals", "definition": "Total number of conventional or small molecule medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 80, "value_text": "80", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "quote": "These include 80 conventional medicines such as small molecules, peptides, and nucleic acids, as well as 40 biologic therapies such as monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_8V30JK5MA813ART823V6ZF2J7Y", "bibtex": "@misc{dia2025conventionalzf2j7y,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8V30JK5MA813ART823V6ZF2J7Y},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "url": "https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "indicator": { "slug": "cumulative-drug-approval-applications-under-priority-review", "name": "Cumulative drug approval applications under priority review", "definition": "Total cumulative number of drug approval applications granted priority review status since program inception." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "point" }, "value": 496, "value_text": "496", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX", "bibtex": "@misc{statecouncil2024cumulative0hd2xx,\n author = {{State Council of China}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX},\n note = {Original source: https://english.www.gov.cn/news/202503/20/content\\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "url": "https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "indicator": { "slug": "cumulative-drug-approval-applications-under-priority-review-annual", "name": "Cumulative drug approval applications under priority review (annual)", "definition": "Total cumulative number of drug approval applications granted priority review status since program inception." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 496, "value_text": "496", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "bibtex": "@misc{nmpa2024cumulative6f0pt1,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_20KAVP0JDSCT0QSHHFHFN0978Z", "url": "https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z", "indicator": { "slug": "cumulative-drugs-added-via-negotiation-in-reimbursement-drug-list", "name": "Cumulative drugs added via negotiation in reimbursement drug list", "definition": "Cumulative number of drugs added to a reimbursement drug formulary through price negotiations." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 530, "value_text": "530种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "自成立以来，国家医保局已连续7年开展药品目录调整工作，累计将835种药品新增进入国家医保药品目录，其中谈判新增530种，竞价新增38种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z", "bibtex": "@misc{nhsa2024cumulativen0978z,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_20KAVP0JDSCT0QSHHFHFN0978Z},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "url": "https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "indicator": { "slug": "cumulative-drugs-removed-from-reimbursement-drug-list", "name": "Cumulative drugs removed from reimbursement drug list", "definition": "Cumulative number of drugs delisted or phased out from a reimbursement drug formulary." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 438, "value_text": "438种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "同时438种疗效不确切或易滥用、临床已被淘汰、长期未生产供应且可被其他品种替代的药品被调出目录。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6", "bibtex": "@misc{nhsa2024cumulativepxj5e6,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R4BFZ4RSKF5KHH2QQKRCPXJ5E6},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_640MTW4RSR1CFHGBHRK9NV0ZST", "url": "https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST", "indicator": { "slug": "cumulative-health-insurance-fund-payout-for-negotiated-medicines", "name": "Cumulative health insurance fund payout for negotiated medicines", "definition": "Cumulative expenditures paid by the basic medical insurance fund for medicines under negotiation agreements." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 350, "value_text": "超过3500亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保基金为协议期内谈判药品支付累计超过3500亿元，惠及患者8.3亿人次。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST", "bibtex": "@misc{statecouncil2024cumulativenv0zst,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_640MTW4RSR1CFHGBHRK9NV0ZST},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_W4J65YEFH7G94MC1DDV7JPRX95", "url": "https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95", "indicator": { "slug": "cumulative-negotiated-drug-sales-during-agreement-period", "name": "Cumulative negotiated drug sales during agreement period", "definition": "Total sales revenue generated by newly negotiated medicines during their agreement period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 510, "value_text": "超5100亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "State Council of China", "org_short_name": "State Council", "org_url": "https://www.gov.cn", "org_tier": 1, "document_title": "2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网", "document_url": "https://www.gov.cn/zhengce/202411/content_6989980.htm", "document_type": "press_release", "locator": "7年累计将835种药品新增进入目录", "quote": "截至2024年10月底，医保谈判新增药品协议期内销售超5100亿元，医保基金支出超3500亿元，如此大规模的资金主要是在原有支出结构中进行优化调整，没有大幅增加群众缴费负担。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "State Council of China. (2024). 2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药_政策解读_中国政府网. Retrieved September 17, 2026, from https://www.gov.cn/zhengce/202411/content_6989980.htm. Via StatOrigin, https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95", "bibtex": "@misc{statecouncil2024cumulativejprx95,\n author = {{State Council of China}},\n title = {2024年版国家医保药品目录出炉，新增91种药品——让参保人用上更多新药好药\\_政策解读\\_中国政府网},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_W4J65YEFH7G94MC1DDV7JPRX95},\n note = {Original source: https://www.gov.cn/zhengce/202411/content\\_6989980.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FQKK442S68TP34CE2YQA8Y69Y6", "url": "https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6", "indicator": { "slug": "cumulative-newly-added-drugs-in-reimbursement-drug-list", "name": "Cumulative newly added drugs in reimbursement drug list", "definition": "Cumulative number of drugs newly added to a reimbursement drug formulary across adjustment cycles." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-05-31", "end": "2024-11-28", "type": "point" }, "value": 835, "value_text": "835种", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "自成立以来，国家医保局已连续7年开展药品目录调整工作，累计将835种药品新增进入国家医保药品目录，其中谈判新增530种，竞价新增38种。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6", "bibtex": "@misc{nhsa2024cumulative8y69y6,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FQKK442S68TP34CE2YQA8Y69Y6},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VEV3PWG150363YY6MZ64Q5ZNDV", "url": "https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV", "indicator": { "slug": "cumulative-patient-burden-reduction-from-negotiated-drugs", "name": "Cumulative patient burden reduction from negotiated drugs", "definition": "Cumulative out-of-pocket healthcare expense savings achieved by patients through price-negotiated reimbursement drugs." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2018-01-01", "end": "2024-10-31", "type": "point" }, "value": 880, "value_text": "超8800亿元", "unit": "CNY", "currency": "CNY", "scale": "billion", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "document_url": "https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html", "document_type": "press_release", "locator": "国家医保局 人力资源社会保障部印发2024年版国家医保药品目录", "quote": "截至2024年10月底，协议期内谈判药品累计受益8.3亿人次，累计为患者减负超8800亿元，充分彰显党和政府对人民健康福祉的高度关切。", "published_date": "2024-11-28", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2024). 国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2024/11/28/art_14_14884.html. Via StatOrigin, https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV", "bibtex": "@misc{nhsa2024cumulativeq5zndv,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VEV3PWG150363YY6MZ64Q5ZNDV},\n note = {Original source: https://www.nhsa.gov.cn/art/2024/11/28/art\\_14\\_14884.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_HX2SN17CSNNB5GG65WGM5HYS9P", "url": "https://statorigin.org/stat/stat_HX2SN17CSNNB5GG65WGM5HYS9P", "indicator": { "slug": "domestic-contribution-to-new-entrant-increase", "name": "Domestic contribution to new entrant increase", "definition": "Percentage contribution of domestic pharmaceutical developers to the net annual increase in new drug market entrants." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 81, "value_text": "81%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Domestic Players Account for Most of China’s Approvals", "quote": "In 2025, China’s innovative drug industry continued its strong development momentum and was responsible for 81% of the increase in new entrants, marking the first time that local product approvals outnumbered foreign arrivals.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_HX2SN17CSNNB5GG65WGM5HYS9P", "bibtex": "@misc{dia2025domestic5hys9p,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_HX2SN17CSNNB5GG65WGM5HYS9P},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_C33EETRSSYZ299C5SMBA9KH6MQ", "url": "https://statorigin.org/stat/stat_C33EETRSSYZ299C5SMBA9KH6MQ", "indicator": { "slug": "domestic-developer-drug-approvals", "name": "Domestic developer drug approvals", "definition": "Total number of approved new medicines originated and developed by domestic pharmaceutical enterprises." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 63, "value_text": "63", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Domestic Players Account for Most of China’s Approvals", "quote": "Among the 120 new medicines cleared by the NMPA, 63 came from domestic developers, representing 52% of the total.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_C33EETRSSYZ299C5SMBA9KH6MQ", "bibtex": "@misc{dia2025domestic9kh6mq,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_C33EETRSSYZ299C5SMBA9KH6MQ},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_403RP3RYGKCERYWB5XRN3S34KH", "url": "https://statorigin.org/stat/stat_403RP3RYGKCERYWB5XRN3S34KH", "indicator": { "slug": "domestic-developer-share-of-drug-approvals", "name": "Domestic developer share of drug approvals", "definition": "Share of total approved new medicines developed by domestic pharmaceutical companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 52, "value_text": "52%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "DIA", "org_short_name": "DIA", "org_url": "https://www.diaglobal.org", "org_tier": 2, "document_title": "2025 NMPA Approvals: China Clears Record Number of New Drugs", "document_url": "https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/", "document_type": "press_release", "locator": "Domestic Players Account for Most of China’s Approvals", "quote": "Among the 120 new medicines cleared by the NMPA, 63 came from domestic developers, representing 52% of the total.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "DIA. (2025). 2025 NMPA Approvals: China Clears Record Number of New Drugs. Retrieved September 17, 2026, from https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Via StatOrigin, https://statorigin.org/stat/stat_403RP3RYGKCERYWB5XRN3S34KH", "bibtex": "@misc{dia2025domestic3s34kh,\n author = {{DIA}},\n title = {2025 NMPA Approvals: China Clears Record Number of New Drugs},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_403RP3RYGKCERYWB5XRN3S34KH},\n note = {Original source: https://globalforum.diaglobal.org/issue/march-2026/2025-nmpa-approvals-china-clears-record-number-of-new-drugs/. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YNSMX436YHHD8Z81G9V98C62GK", "url": "https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK", "indicator": { "slug": "domestic-first-in-class-drug-approvals", "name": "Domestic first-in-class drug approvals", "definition": "Number of approved first-in-class drugs with novel mechanisms of action originated by domestic developers." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "4个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "2025年我国批准的首创新药为11个，其中4个是我国自主研发的。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK", "bibtex": "@misc{nhsa2025domestic8c62gk,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YNSMX436YHHD8Z81G9V98C62GK},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_H0A44FGGE45T9X6BB14NAY01YN", "url": "https://statorigin.org/stat/stat_H0A44FGGE45T9X6BB14NAY01YN", "indicator": { "slug": "domestic-first-in-class-drug-approvals", "name": "Domestic first-in-class drug approvals", "definition": "Number of approved first-in-class drugs with novel mechanisms of action originated by domestic developers." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "4个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Ministry of Commerce of China", "org_short_name": "MOFCOM", "org_url": "https://www.mofcom.gov.cn", "org_tier": 1, "document_title": "2025年我国批准创新药76个 对外授权超千亿美元", "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html", "document_type": "press_release", "locator": "2025年我国批准创新药76个 对外授权超千亿美元", "quote": "根据国家药监局数据，2025年76个审批的创新药中，有11个是首创新药，但其中仅有4个是国内本土研发。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Ministry of Commerce of China. (2025). 2025年我国批准创新药76个 对外授权超千亿美元. Retrieved September 17, 2026, from https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Via StatOrigin, https://statorigin.org/stat/stat_H0A44FGGE45T9X6BB14NAY01YN", "bibtex": "@misc{mofcom2025domesticay01yn,\n author = {{Ministry of Commerce of China}},\n title = {2025年我国批准创新药76个 对外授权超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H0A44FGGE45T9X6BB14NAY01YN},\n note = {Original source: https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PJ5VPBW3DD20GZHP95QV5524P7", "url": "https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7", "indicator": { "slug": "domestic-innovative-biological-product-approvals", "name": "Domestic innovative biological product approvals", "definition": "Number of domestically originated innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 21, "value_text": "21个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7", "bibtex": "@misc{nhsa2025domestic5524p7,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PJ5VPBW3DD20GZHP95QV5524P7},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_TXCRG6H99JJA44HK338F298NKM", "url": "https://statorigin.org/stat/stat_TXCRG6H99JJA44HK338F298NKM", "indicator": { "slug": "domestic-innovative-biological-product-approvals", "name": "Domestic innovative biological product approvals", "definition": "Number of domestically originated innovative biological medicines granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 21, "value_text": "21个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Ministry of Commerce of China", "org_short_name": "MOFCOM", "org_url": "https://www.mofcom.gov.cn", "org_tier": 1, "document_title": "2025年我国批准创新药76个 对外授权超千亿美元", "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html", "document_type": "press_release", "locator": "2025年我国批准创新药76个 对外授权超千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Ministry of Commerce of China. (2025). 2025年我国批准创新药76个 对外授权超千亿美元. Retrieved September 17, 2026, from https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Via StatOrigin, https://statorigin.org/stat/stat_TXCRG6H99JJA44HK338F298NKM", "bibtex": "@misc{mofcom2025domestic298nkm,\n author = {{Ministry of Commerce of China}},\n title = {2025年我国批准创新药76个 对外授权超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_TXCRG6H99JJA44HK338F298NKM},\n note = {Original source: https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "url": "https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "indicator": { "slug": "domestic-innovative-chemical-drug-approvals", "name": "Domestic innovative chemical drug approvals", "definition": "Number of domestically originated innovative chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 38, "value_text": "38个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Healthcare Security Administration", "org_short_name": "NHSA", "org_url": "https://www.nhsa.gov.cn", "org_tier": 1, "document_title": "国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元", "document_url": "https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html", "document_type": "press_release", "locator": "创新高！去年我国批准创新药76个 对外授权破千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Healthcare Security Administration. (2025). 国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元. Retrieved September 17, 2026, from https://www.nhsa.gov.cn/art/2026/1/18/art_14_19392.html. Via StatOrigin, https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W", "bibtex": "@misc{nhsa2025domesticgkrp5w,\n author = {{National Healthcare Security Administration}},\n title = {国家医疗保障局 医保动态 创新高！去年我国批准创新药76个 对外授权破千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P51Z5CB5E0RWSQBPPWKJGKRP5W},\n note = {Original source: https://www.nhsa.gov.cn/art/2026/1/18/art\\_14\\_19392.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Y05J4BZKQ3T9QTTA0N2TRGP56M", "url": "https://statorigin.org/stat/stat_Y05J4BZKQ3T9QTTA0N2TRGP56M", "indicator": { "slug": "domestic-innovative-chemical-drug-approvals", "name": "Domestic innovative chemical drug approvals", "definition": "Number of domestically originated innovative chemical drugs granted regulatory marketing approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 38, "value_text": "38个", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Ministry of Commerce of China", "org_short_name": "MOFCOM", "org_url": "https://www.mofcom.gov.cn", "org_tier": 1, "document_title": "2025年我国批准创新药76个 对外授权超千亿美元", "document_url": "https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html", "document_type": "press_release", "locator": "2025年我国批准创新药76个 对外授权超千亿美元", "quote": "47个化学药品中，38个为国产创新药，9个为进口创新药，国产创新药占比达80.85%；23个生物制品中，21个为国产创新药，2个为进口创新药，国产创新药占比达91.30%。", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Ministry of Commerce of China. (2025). 2025年我国批准创新药76个 对外授权超千亿美元. Retrieved September 17, 2026, from https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Via StatOrigin, https://statorigin.org/stat/stat_Y05J4BZKQ3T9QTTA0N2TRGP56M", "bibtex": "@misc{mofcom2025domesticrgp56m,\n author = {{Ministry of Commerce of China}},\n title = {2025年我国批准创新药76个 对外授权超千亿美元},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y05J4BZKQ3T9QTTA0N2TRGP56M},\n note = {Original source: https://tradeinservices.mofcom.gov.cn/article/hyly/zyy/zyyfwbmdt/202601/180991.html. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ], "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 195, "limit": 50, "next_cursor": "eyJvIjo1MH0=" } }